1. Computational modeling in melanoma for novel drug discovery
    Marzio Pennisi et al, 2016, Expert Opinion on Drug Discovery CrossRef
  2. Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs
    Simona Serini et al, 2017, Nutrients CrossRef
  3. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor
    Jean-Marc Lapierre et al, 2016, J. Med. Chem. CrossRef
  4. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1
    Brajendra K. Tripathi et al, 2017, J. Cell Biol. CrossRef
  5. Triangle of AKT2, miRNA, and Tumorigenesis in Different Cancers
    Maryam Honardoost et al, 2017, Appl Biochem Biotechnol CrossRef
  6. A central role for PI3K-AKT signaling pathway in linking SAMHD1-deficiency to the type I interferon signature
    Changhoon Oh et al, 2018, Sci Rep CrossRef
  7. Inhibition of CCR7 promotes NF-κB-dependent apoptosis and suppresses epithelial-mesenchymal transition in non-small cell lung cancer
    Lan Zhang et al, 2017 CrossRef
  8. Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
    Fadi J Najm et al, 2017, Nat Biotechnol CrossRef
  9. Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies
    Ali Razaghi et al, 2018, Apoptosis CrossRef
  10. Alphavirus-induced hyperactivation of PI3K/AKT directs pro-viral metabolic changes
    Michela Mazzon et al, 2018, PLoS Pathog CrossRef
  11. Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing
    Ahmad M. Alamri et al, 2018, Dis. Model. Mech. CrossRef
  12. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
    Jake S. O’Donnell et al, 2018, Seminars in Cancer Biology CrossRef
  13. AGC kinases, mechanisms of regulation ‎and innovative drug development
    Alejandro E. Leroux et al, 2018, Seminars in Cancer Biology CrossRef
  14. Libidibia ferrea presents antiproliferative, apoptotic and antioxidant effects in a colorectal cancer cell line
    Andreza Conceição Véras de Aguiar Guerra et al, 2017, Biomedicine & Pharmacotherapy CrossRef
  15. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer
    Linnéa Malgerud et al, 2017, Mol Oncol CrossRef
  16. Ligand-based modeling of Akt3 Lead to Potent Dual Akt1/Akt3 Inhibitor
    Mahmoud A. Al-Sha et al, 2018, Journal of Molecular Graphics and Modelling CrossRef
  17. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
    Nahal Haddadi et al, 2018, Mol Cancer CrossRef
  18. Protein Kinase Targets in Breast Cancer
    Marilina García-Aranda et al, 2017, IJMS CrossRef
  19. EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer
    Shaoxin Cai et al, 2018, Experimental Cell Research CrossRef
  20. null
    Tuo-Xian Tang et al, 2017 CrossRef
  21. AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
    Sanja Brolih et al, 2018, BMC Cancer CrossRef
  22. Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma
    Hongyang Lu et al, 2018, BMC Cancer CrossRef
  23. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
    C. Ranieri et al, 2018, Neurogenetics CrossRef
  24. Concurrent interactome and metabolome analysis reveals role of AKT1 in central carbon metabolism
    Nutan Gupta et al, 2018, BMC Res Notes CrossRef
  25. null
    , 2018 CrossRef
  26. The Flavonoid Jaceosidin from Artemisia princeps Induces Apoptotic Cell Death and Inhibits the Akt Pathway in Oral Cancer Cells
    Hye-Yeon Han et al, 2018, Evidence-Based Complementary and Alternative Medicine CrossRef
  27. Anticancer Activity of Euplotin C, Isolated from the Marine Ciliate Euplotes crassus, Against Human Melanoma Cells
    Sara Carpi et al, 2018, Marine Drugs CrossRef
  28. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
    Antoine Buetti-Dinh et al, 2018, BMC Cancer CrossRef
  29. Design, Synthesis, and Evaluation of a New Series of Thiazole-Based Anticancer Agents as Potent Akt Inhibitors
    Mehlika Altıntop et al, 2018, Molecules CrossRef
  30. The FOXO3-FOXM1 Axis: a key Cancer Drug Target and a Modulator of Cancer Drug Resistance
    Shang Yao et al, 2017, Seminars in Cancer Biology CrossRef
  31. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors
    Mehlika Dilek Altıntop et al, 2018, European Journal of Medicinal Chemistry CrossRef
  32. Saponins From Paris forrestii (Takht.) H. Li Display Potent Activity Against Acute Myeloid Leukemia by Suppressing the RNF6/AKT/mTOR Signaling Pathway
    Qin Lu et al, 2018, Front. Pharmacol. CrossRef
  33. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.
    L M FitzGerald et al, 2018, Prostate Cancer Prostatic Dis CrossRef
  34. MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potential hypocholesterolemic agent
    Katrine Bjune et al, 2018, Atherosclerosis CrossRef
  35. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design
    Michelle S. Miller et al, 2017, Bioorganic & Medicinal Chemistry CrossRef
  36. Chemical modulation of transcription factors
    Bianca Wiedemann et al, 2018, Med. Chem. Commun. CrossRef
  37. Big Data Approaches for Modeling Response and Resistance to Cancer Drugs
    Peng Jiang et al, 2018, Annu. Rev. Biomed. Data Sci. CrossRef
  38. 27-hydroxycholesterol decreases cell proliferation in colon cancer cell lines
    Jessica Warns et al, 2018, Biochimie CrossRef
  39. MicroRNA-191, acting via the IRS-1/Akt signaling pathway, is involved in the hepatic insulin resistance induced by cigarette smoke extract
    Qianlei Yang et al, 2018, Environ Sci Pollut Res CrossRef
  40. Synthesis and dynamic 1 H NMR study of pyrazolo substituted pyrrolo[2,3- d ]pyrimidines via a regioselective heterocyclization
    Mohammad Bayat et al, 2018, Journal of Molecular Structure CrossRef
  41. 1α,25-dihydroxyvitamin D3 inhibits aflatoxin B1-induced proliferation and dedifferentiation of hepatic progenitor cells by regulating PI3K/Akt and Hippo pathways
    Jian Wang et al, 2018, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
  42. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts
    Michael Mc Kenna et al, 2018, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  43. Phosphorylation-Dependent Inhibition of Akt1
    Nileeka Balasuriya et al, 2018, Genes CrossRef
  44. Deficiency of tumor suppressor Merlin facilitates metabolic adaptation by co-operative engagement of SMAD-Hippo signaling in breast cancer
    Mateus S V Mota et al, 2018 CrossRef
  45. Emerging ways to treat breast cancer: will promises be met?
    Pouria Samadi et al, 2018, Cell Oncol. CrossRef
  46. The chemopreventive effect of withaferin A on spontaneous and inflammation-associated colon carcinogenesis models
    Balaji Chandrasekaran et al, 2018 CrossRef
  47. Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma
    Nada M. S. Al-Saffar et al, 2018, Br J Cancer CrossRef
  48. Curcumin ameliorates PRMT5-MEP50 arginine methyltransferase expression by decreasing the Sp1 and NF-YA transcription factors in the A549 and MCF-7 cells
    Biji Chatterjee et al, 2018, Mol Cell Biochem CrossRef
  49. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania
    Devki Nandan et al, 2018, PLoS ONE CrossRef
  50. Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation
    Wei Li et al, 2018, Cell Commun Signal CrossRef
  51. null
    Valentina Uivarosi et al, 2018 CrossRef
  52. Theoretical Investigation of the Structural Characteristics in the Active State of Akt1 Kinase
    Lanxuan Liu et al, 2019, J. Chem. Inf. Model. CrossRef
  53. Targeting allosteric site of AKT by 5,7-dimethoxy-1,4-phenanthrenequinone suppresses neutrophilic inflammation
    Po-Jen Chen et al, 2019, EBioMedicine CrossRef
  54. AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress
    Florencia Villafañez et al, 2019, Oncogene CrossRef
  55. null
    Ewa Świderska et al, 2018 CrossRef
  56. Polyphenols from Pennisetum glaucum grains induce MAP kinase phosphorylation and cell cycle arrest in human osteosarcoma cells
    Abdelhafid Nani et al, 2019, Journal of Functional Foods CrossRef
  57. GAEC1 drives colon cancer progression
    Katherine Ting-Wei Lee et al, 2019, Mol Carcinog CrossRef
  58. The design of 1,4-naphthoquinone derivatives and mechanisms underlying apoptosis induction through ROS-dependent MAPK/Akt/STAT3 pathways in human lung cancer cells.
    Yi Zhang et al, 2019, Bioorg Med Chem CrossRef
  59. Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics
    Kai Wu et al, 2019, Cancer Cell Int CrossRef
  60. A Bayesian random partition model for sequential refinement and coagulation
    Carlos Tadeu Pagani Zanini et al, 2019, Biom CrossRef
  61. Non-canonical Notch Signaling Regulates Actin Remodeling in Cell Migration by Activating PI3K/AKT/Cdc42 Pathway
    Lei Liu et al, 2019, Front. Pharmacol. CrossRef
  62. Insulin transcriptionally down-regulates carboxylesterases through pregnane X receptor in an Akt-dependent manner
    Xuan Yang et al, 2019, Toxicology CrossRef
  63. The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy
    Seyed A. Javadinia et al, 2019, CPD CrossRef
  64. Akt in cancer: Mediator and more.
    Sundaramoorthy Revathidevi et al, 2019, Semin Cancer Biol CrossRef
  65. Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes
    Khadijah A. Mitchell et al, 2019, Urologic Oncology: Seminars and Original Investigations CrossRef
  66. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Ali S Alzahrani, 2019, Semin Cancer Biol CrossRef
  67. RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes.
    Rui-Jie Zeng et al, 2019, Mol Oncol CrossRef
  68. Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation
    Chao-Yuan Huang et al, 2018, J Pharmacol Exp Ther CrossRef
  69. Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1β release
    Amanda J. Iacano et al, 2019, Sci Rep CrossRef
  70. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer.
    VarRuchi Sharma et al, 2019, Semin Cancer Biol CrossRef
  71. Recent Advance of Akt Inhibitors in Clinical Trials
    Kaiwen Guo et al, 2019, ChemistrySelect CrossRef
  72. Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells
    null Gener et al, 2019, Cancers CrossRef
  73. MicroRNA-21 activation of Akt via PTEN is involved in the epithelial–mesenchymal transition and malignant transformation of human keratinocytes induced by arsenite
    Xiaolin Lu et al, 2016, Toxicol. Res. CrossRef
  74. Effects of resveratrol on carbon monoxide-induced cardiotoxicity in rats
    Mahmoud Hashemzaei et al, 2016, Environmental Toxicology and Pharmacology CrossRef
  75. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer
    Hyun-Jeong Ko et al, 2016, Arch. Pharm. Res. CrossRef
  76. The dark side of the moon: AKT as a tumor suppressor in the liver?
    Xin Chen et al, 2016, Hepatology CrossRef
  77. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
    Nicola Bougen-Zhukov et al, 2019, Cancers CrossRef
  78. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma
    Brian H. Kushner et al, 2017, Int. J. Cancer CrossRef
  79. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development
    Liliana Guerra et al, 2017, Matrix Biology CrossRef
  80. Alkylphospholipids: An update on molecular mechanisms and clinical relevance
    Pablo Ríos-Marco et al, 2017, Biochimica et Biophysica Acta (BBA) - Biomembranes CrossRef
  81. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
    Yi Yu et al, 2017, Anti-Cancer Drugs CrossRef
  82. The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells
    Slavica Vuckovic et al, 2017, Br J Haematol CrossRef
  83. Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activity
    Marius Mioc et al, 2017 CrossRef
  84. Cross-talk between the CK2 and AKT signaling pathways in cancer
    Maria Ruzzene et al, 2017, Advances in Biological Regulation CrossRef
  85. Protein kinase B
    Bhumika Wadhwa et al, 2017, Anti-Cancer Drugs CrossRef
  86. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib
    Eri Banno et al, 2017 CrossRef
  87. Clusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancer
    Marilina García-Aranda et al, 2017, Anti-Cancer Drugs CrossRef
  88. Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model
    Sara Ramezani et al, 2017, Apoptosis CrossRef
  89. The T-Box transcription factor 3 in development and cancer
    Tarryn Willmer et al, 2017, BST CrossRef
  90. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity
    Yang Liu et al, 2017, European Journal of Medicinal Chemistry CrossRef
  91. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
    Masayuki Yamaji et al, 2017, Cancer Med CrossRef
  92. Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt
    Bill X. Huang et al, 2017, Sci Rep CrossRef
  93. Intravenous miR-144 inhibits tumor growth in diethylnitrosamine-induced hepatocellular carcinoma in mice
    Quan He et al, 2017, Tumour Biol. CrossRef
  94. Network dynamics-based cancer panel stratification for systemic prediction of anticancer drug response
    Minsoo Choi et al, 2017, Nat Commun CrossRef
  95. Genipin, a natural AKT inhibitor, targets the PH domain to affect downstream signaling and alleviates inflammation
    Yanting Jiao et al, 2019, Biochemical Pharmacology CrossRef
  96. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer
    Thirumal Kumar D et al, 2019, Computers in Biology and Medicine CrossRef
  97. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
    Mohamed Rizk et al, 2019, Cancer Sci CrossRef
  98. Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies
    Guillaume Robert et al, 2019, Cells CrossRef
  99. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases
    Samuel J. Rodgers et al, 2017 CrossRef
  100. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy.
    Ali F Abdel-Wahab et al, 2019, Pharmacol Res CrossRef
  101. The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells
    Yu-Liang Li et al, 2019, Front. Pharmacol. CrossRef
  102. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance
    Meshach Asare-Werehene et al, 2019, Oncogene CrossRef
  103. In Vitro and In Vivo Antitumor Activity of Cucurbitacin C, a Novel Natural Product From Cucumber
    Dinglan Wu et al, 2019, Front. Pharmacol. CrossRef
  104. Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
    Lena Quambusch et al, 2019, Angew. Chem. CrossRef
  105. Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity
    Lena Quambusch et al, 2019, Angew. Chem. Int. Ed. CrossRef
  106. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis
    Mohammed Salah Ayoup et al, 2019, European Journal of Medicinal Chemistry CrossRef
  107. Distinct functions of AKT isoforms in breast cancer: a comprehensive review.
    Nico Hinz et al, 2019, Cell Commun Signal CrossRef
  108. null
    Saimila Momin et al, 2019 CrossRef
  109. Computational investigation of imidazopyridine analogs as Protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations
    Xi Gu et al, 2019, Journal of Biomolecular Structure and Dynamics CrossRef
  110. Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma
    Franziska Gehringer et al, 2019, Leukemia CrossRef
  111. Emerging serine-threonine kinase inhibitors for treating ovarian cancer
    Asaf Maoz et al, 2019, Expert Opinion on Emerging Drugs CrossRef
  112. Rosemary Extract Inhibits Proliferation, Survival, Akt, and mTOR Signaling in Triple-Negative Breast Cancer Cells
    Alina Jaglanian et al, 2020, IJMS CrossRef
  113. FOXM1: a potential therapeutic target in human solid cancers.
    Soheila Borhani et al, 2020, Expert Opin Ther Targets CrossRef
  114. Spotlight on AKT: Current Therapeutic Challenges
    Ina Landel et al, 2020, ACS Med. Chem. Lett. CrossRef
  115. Advances in covalent kinase inhibitors
    Ayah Abdeldayem et al, 2020, Chem. Soc. Rev. CrossRef
  116. New furochromone derivatives as promising in-vitro anti-proliferative agents toward HepG-2 and MCF-7 cell lines with molecular docking studies
    Nagwa M. Fawzy et al, 2020, J Heterocyclic Chem CrossRef
  117. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
    Parham Jabbarzadeh Kaboli et al, 2020, Pharmacol Res CrossRef
  118. Knockdown of Rab9 Suppresses the Progression of Gastric Cancer Through Regulation of Akt Signaling Pathway
    Yong Zhu et al, 2020, Technol Cancer Res Treat CrossRef
  119. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells
    Qiaoling Song et al, 2017, Oncotarget CrossRef
  120. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines
    Synnøve Yndestad et al, 2017, Oncotarget CrossRef
  121. Precision Targeting of pten-Null Triple-Negative Breast Tumors Guided by Electrophilic Metabolite Sensing
    Xuyu Liu et al, 2020, ACS Cent. Sci. CrossRef
  122. Inhibitors in AKTion: ATP-competitive vs allosteric
    Glorianne Lazaro et al, 2020 CrossRef
  123. The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling
    Durdana Waseem et al, 2020, Toxicology and Applied Pharmacology CrossRef
  124. null
    Mei-Kuang Chen et al, 2020 CrossRef
  125. Akt Pathway Inhibitors
    Nne E. Uko et al, 2020, CTMC CrossRef
  126. Genetic alterations in anaplastic thyroid carcinoma and targeted therapies (Review)
    Zongjuan Li et al, 2019, Exp Ther Med CrossRef
  127. Knockdown of DUXAP10 inhibits proliferation and promotes apoptosis in bladder cancer cells via PI3K/Akt/mTOR signaling pathway
    Xiu-Yi Lv et al, 2017, Int J Oncol CrossRef
  128. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review)
    George Nitulescu et al, 2020, Int J Mol Med CrossRef
  129. The Akt pathway in oncology therapy and beyond (Review).
    George Mihai Nitulescu et al, 2018, Int J Oncol CrossRef
  130. The protective effect of soybean protein‐derived peptides on apoptosis via the activation of PI3K‐AKT and inhibition on apoptosis pathway
    Guofu Yi et al, 2020, Food Sci Nutr CrossRef
  131. Anticancer Agents Based on Vulnerable Components in a Signalling Pathway
    Ankur Vaidya et al, 2020, MRMC CrossRef
  132. BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells
    Bin Ma et al, 2020 CrossRef
  133. Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo
    Loral Showalter et al, 2020, Oncotarget CrossRef
  134. The structural determinants of PH domain-mediated regulation of Akt revealed by segmental labeling
    Nam Chu et al, 2020 CrossRef
  135. Polyphenolic Proanthocyanidin-B2 Suppresses Proliferation of Liver Cancer Cells and Hepatocellular Carcinogenesis through Directly Binding and Inhibiting AKT Activity
    Guijun Liu et al, 2020, Redox Biology CrossRef
  136. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
    Salihanur Darici et al, 2020, JCM CrossRef
  137. USP46 Inhibits Cell Proliferation in Lung Cancer through PHLPP1/AKT Pathway
    Wei Wang et al, 2020, BioMed Research International CrossRef

  138. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer


    Jinhong Shi et al, 2020, CMAR CrossRef
  139. Development and characterization of protein kinase B/AKT isoform-specific nanobodies
    Tijs Merckaert et al, 2020, PLoS ONE CrossRef
  140. Synthesis, In Silico and In Vitro Assessment of New Quinazolinones as Anticancer Agents via Potential AKT Inhibition
    Ahmed A. Noser et al, 2020, Molecules CrossRef
  141. Crosslink among phosphatidylinositol-3 kinase/Akt, PTEN and STAT-5A signaling pathways post liposomal galactomannan hepatocellular carcinoma therapy
    Rehab M. Abdel-Megeed et al, 2020, Toxicology Reports CrossRef
  142. MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer
    Ammar Sarwar et al, 2020, Biochemical Pharmacology CrossRef
  143. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
    Yumi Fujimoto et al, 2020, Sci Rep CrossRef
  144. Akt Signaling Is Sustained by a CD44 Splice Isoform-Mediated Positive Feedback Loop.
    Sali Liu et al, 0 CrossRef
  145. AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis
    David A. Kircher et al, 2019, Mol Cancer Res CrossRef
  146. Chemotherapeutic Agents Targeting Intracellular Signaling Pathways
    Sevgi Uğur MUTLUAY et al, 2021 CrossRef
  147. Phospho-Form Specific Substrates of Protein Kinase B (AKT1)
    McShane McKenna et al, 2021, Front. Bioeng. Biotechnol. CrossRef
  148. The Roles of Post-Translational Modifications on mTOR Signaling
    Shasha Yin et al, 2021, IJMS CrossRef
  149. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors
    Di Wu et al, 2021, Cell Reports CrossRef
  150. Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment
    Mariam Mroweh et al, 2021, IJMS CrossRef
  151. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions
    Ayda Baghery Saghchy Khorasani et al, 2021, European Journal of Pharmacology CrossRef
  152. AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation
    Jia Mai et al, 2021, Oncogene CrossRef
  153. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
    Anna Richter et al, 2021, IJMS CrossRef
  154. Design, Synthesis, In vitro and In silico Evaluation of New Hydrazonebased Antitumor Agents as Potent Akt Inhibitors
    Emine Merve Güngör et al, 2020, LDDD CrossRef
  155. Central and peripheral emetic loci contribute to vomiting evoked by the Akt inhibitor MK-2206 in the least shrew model of emesis
    Weixia Zhong et al, 2021, European Journal of Pharmacology CrossRef
  156. Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
    Lingzhu Wen et al, 2021, CMAR CrossRef
  157. Implication of integrins α3β1 and α5β1 in invasion and anoikis of SK-Mel-147 human melanoma cells: non-canonical functions of protein kinase Akt
    Nadezhda I. Kozlova et al, 2020, Aging CrossRef
  158. The importance of Ras in drug resistance in cancer
    Fiona M. Healy et al, 2021, Br J Pharmacol CrossRef
  159. Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation
    Dimitrios T. Trafalis et al, 2021, Pharmaceutics CrossRef
  160. AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery
    Amit Kumar Halder et al, 2021, IJMS CrossRef
  161. How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer
    Said M. Afify et al, 2021, Expert Review of Anticancer Therapy CrossRef
  162. Upregulated hsa_circRNA_100269 inhibits the growth and metastasis of gastric cancer through inactivating PI3K/Akt axis.
    Zhongli Wang et al, 2021, PLoS One CrossRef
  163. Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
    Chelsea Schiliro et al, 2021, Cells CrossRef
  164. Boolean dynamic modeling of cancer signaling networks: Prognosis, progression, and therapeutics
    Shubhank Sherekar et al, 2021, Comp Sys Onco CrossRef
  165. Exploration of therapeutic applicability and different signaling mechanism of various phytopharmacological agents for treatment of breast cancer
    Vandana Singh et al, 2021, Biomedicine & Pharmacotherapy CrossRef
  166. Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
    Maria Maddalena Laterza et al, 2021, Cancers CrossRef
  167. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis
    Shasha Yin et al, 2021, Nat Commun CrossRef
  168. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
    Clara Alcon et al, 2021, Cells CrossRef
  169. FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
    Mikhail S Chesnokov et al, 2021, Front. Oncol. CrossRef
  170. Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
    Nazanin Momeni Roudsari et al, 2021, Pharmaceutics CrossRef
  171. Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell Carcinoma
    Joaquín Yanes-Díaz et al, 2021, Pharmaceutics CrossRef
  172. Identification of miRNAs and related hub genes associated with the triple negative breast cancer using integrated bioinformatics analysis and in vitro approach
    Mohd Shuaib et al, 2021, Journal of Biomolecular Structure and Dynamics CrossRef
  173. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL‐1 cell growth
    J. H. Wu et al, 2021, Clin Exp Dermatol CrossRef
  174. Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
    Christiana M. Neophytou et al, 2021, Cancers CrossRef
  175. Cellular model system to dissect the isoform-selectivity of Akt inhibitors
    Lena Quambusch et al, 2021, Nat Commun CrossRef
  176. The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
    Hannah Zaryouh et al, 2021, Front. Oncol. CrossRef
  177. Synthesis, Molecular Docking and Biological Evaluation of Novel Flavone Derivatives as Potential Anticancer Agents Targeting Akt
    Heba M. Abo-Salem et al, 2020, MC CrossRef
  178. Hydroquinone 5-O-Cinnamoyl Ester of Renieramycin M Suppresses Lung Cancer Stem Cells by Targeting Akt and Destabilizes c-Myc
    Nattamon Hongwiangchan et al, 2021, Pharmaceuticals CrossRef
  179. The role of PI3'‐lipid signalling in melanoma initiation, progression and maintenance
    Gennie L. Parkman et al, 2021, Exp Dermatol CrossRef
  180. null
    Soumen Bera et al, 2021 CrossRef
  181. Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells
    Tapas Patra et al, 2021, Cell Death Dis CrossRef
  182. Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?
    Benoîte Mery et al, 2021, IJMS CrossRef
  183. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
    Xufen Yu et al, 2021, J. Med. Chem. CrossRef
  184. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress
    Parham Jabbarzadeh Kaboli et al, 2022, Gene CrossRef
  185. The role of the STAT3 signaling transduction pathways in radioresistance
    Po-Chang Shihs, 2022, Pharmacology & Therapeutics CrossRef
  186. null
    Fei Ji et al, 2022 CrossRef
  187. null
    Soumen Bera et al, 2022 CrossRef
  188. Tyrosine kinase inhibitors in breast cancer (Review)
    George Iancu et al, 2021, Exp Ther Med CrossRef
  189. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure–Activity Relationship Studies
    Xufen Yu et al, 2022, J. Med. Chem. CrossRef
  190. New Advances in Targeted Therapy of HER2-Negative Breast Cancer
    Junsha An et al, 2022, Front. Oncol. CrossRef
  191. Syringic and ascorbic acids prevent NDMA-induced pulmonary fibrogenesis, inflammation, apoptosis, and oxidative stress through the regulation of PI3K-Akt/PKB-mTOR-PTEN signaling pathway
    Oluwatobi T. Somade et al, 2022, Metabolism Open CrossRef
  192. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
    Aleksandra Sochacka-Ćwikła et al, 2022, Molecules CrossRef
  193. Bithiophene derivative induced apoptosis and suppression of Akt pathway in mouse leukemic model
    Ali Samy Algharib et al, 2022, TUB CrossRef
  194. Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors
    Kristin M. Zimmerman Savill et al, 2022, Nat Commun CrossRef
  195. The Importance of RTK Signaling Genes and their Inhibitors in Breast Cancer
    Maryam Rahimi et al, 2022, J Obstet Gynecol Cancer Res CrossRef
  196. Ultrasound assisted one-pot synthesis of rosuvastatin based novel azaindole derivatives via coupling-cyclization strategy under Pd/Cu-catalysis: their evaluation as potential cytotoxic agents
    Jetta Sandeep Kumar et al, 2022, Bioorganic Chemistry CrossRef
  197. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene
    Kai Chen et al, 2020, Life Sciences CrossRef
  198. Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development
    Rajeev Kharb, 2021, ACAMC CrossRef
  199. AKT constitutes a signal-promoted alternative exon-junction complex that regulates nonsense-mediated mRNA decay
    Hana Cho et al, 2022, Molecular Cell CrossRef
  200. Synthetic Vulnerabilities in the KRAS Pathway
    Marta Roman et al, 2022, Cancers CrossRef
  201. Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader
    Cheng-Liang Zhu et al, 2022, European Journal of Medicinal Chemistry CrossRef
  202. A Novel Isaindigotone Derivative Displays Better Anti-Proliferation Activities and Induces Apoptosis in Gastric Cancer Cells
    Kangjia Du et al, 2022, IJMS CrossRef
  203. AKT1 Transcriptomic Landscape in Breast Cancer Cells
    Bijesh George et al, 2022, Cells CrossRef
  204. Targeting Akt/PKB in Pediatric Tumors: A Review From Preclinical to Clinical Trials
    Bruno Toson et al, 2022, Pharmacological Research CrossRef
  205. Anticancer potential of turmeric (Curcuma longa) ethanol extract and prediction of its mechanism through the Akt1 pathway
    Muhammad Hermawan Widyananda et al, 2022, F1000Res CrossRef
  206. A Review on the Design, Synthesis, and Structure-activity Relationships of Benzothiazole Derivatives against Hypoxic Tumors
    Akif Hakan Kurt et al, 2022, COS CrossRef
  207. The Significance of p-AKT1 as a Prognostic Marker and Therapeutic Target in Patients With Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Positive Early Breast Cancer
    Ji Yea Kim et al, 2022, J Breast Cancer CrossRef
  208. RAS: Circuitry and therapeutic targeting
    Gagandeep Singh et al, 2022, Cellular Signalling CrossRef
  209. Development of new 1, 3-dihydroxyacridone derivatives as Akt pathway inhibitors in skeletal muscle cells
    A. Paula Irazoqui et al, 2022, Bioorganic Chemistry CrossRef
  210. Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
    Maria Antonietta Occhiuzzi et al, 2022, European Journal of Medicinal Chemistry CrossRef
  211. Repurposing artemisinins as neuroprotective agents: a focus on the PI3k/Akt signalling pathway
    Richmond Arthur et al, 2022, Naunyn-Schmiedeberg's Arch Pharmacol CrossRef
  212. A new series of thiazole‐hydrazone hybrids for Akt‐targeted therapy of non‐small cell lung cancer
    Turana Orujova et al, 2022, Drug Development Research CrossRef
  213. Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions
    Jindi Huang et al, 2022, J. Med. Chem. CrossRef
  214. Identification of allosteric inhibitor against AKT1 through structure-based virtual screening
    Keerthana Karunakaran et al, 2022, Mol Divers CrossRef
  215. Characterizations of Unusual Peptides Encoded by Circular RNAs and their Possible Involvements in Human Diseases
    Aniruddha Biswas et al, 2022, Proc. Natl. Acad. Sci., India, Sect. B Biol. Sci. CrossRef
  216. Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer
    Georgina L. Gregory et al, 2023, Molecular Therapy - Nucleic Acids CrossRef
  217. Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells.
    Clemens Holz et al, 2023, Int J Mol Sci CrossRef
  218. Tetrandrine inhibits migration and invasion of BGC ‐823 and MKN ‐45 cells by regulating PI3K / AKT / mTOR signaling pathway
    Wanli Xue et al, 2023, Chem Biol Drug Des CrossRef
  219. Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action.
    Mehlika Dilek Altıntop et al, 2023, Int J Mol Sci CrossRef
  220. Metabolomics in oncology
    Gurparsad Singh Suri et al, 2023, Cancer Reports CrossRef
  221. Strategy toward Kinase-Selective Drug Discovery
    Mingzhen Zhang et al, 2023, J. Chem. Theory Comput. CrossRef
  222. Synthesis, cytotoxicity, and docking based analysis of acridone-N-acetamides as AKT kinase inhibitors
    Tanuja T. Yadav et al, 2023, Chem. Pap. CrossRef
  223. Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
    Manzar Alam et al, 2023, Biomedicine & Pharmacotherapy CrossRef
  224. Computational docking and in vitro analysis identifies novel arylidene analogue FPMXY-14 against renal cancer cells by attenuating Akt
    HASSAN M. OTIFI et al, 2021 CrossRef
  225. Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA / AKT / PTEN ‐mutated advanced solid tumors
    Shubham Pant et al, 2023, Cancer CrossRef
  226. Structure-Based Rational Design Enables Discovery of a New Selective and Potent Akt Degrader with Improved Dermatologic Safety
    Cheng-Liang Zhu et al, 2022, SSRN Journal CrossRef
  227. null
    Carmen Avendaño et al, 2023 CrossRef
  228. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
    Mengshu You et al, 2023, Sig Transduct Target Ther CrossRef
  229. Molecular insights into the behavior of the allosteric and ATP-competitive inhibitors in interaction with AKT1 protein: A molecular dynamics study
    Mohammad Reza Amiran et al, 2023, International Journal of Biological Macromolecules CrossRef
  230. Design, synthesis and evaluation of acridone-2-carbohydrazide derivatives as p-AKT Ser473 kinase inhibitors
    Tanuja T Yadav et al, 2023, Future Medicinal Chemistry CrossRef
  231. Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy
    Burak Erdönmez et al, 2023, ACS Omega CrossRef
  232. Canine thyroid carcinomas: A review with emphasis on comparing the compact subtype of follicular thyroid carcinomas and medullary thyroid carcinomas
    Jillian M. Athey et al, 2023, Vet Pathol CrossRef
  233. Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors
    Fine Aliyuda et al, 2023, CCDT CrossRef
  234. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.
    Feng Ye et al, 2023, Mol Cancer CrossRef
  235. The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
    George Mihai Nitulescu et al, 2023, Molecules CrossRef
  236. The regulation of human organic anion transporter 4 by insulin-like growth factor 1 and protein kinase B signaling
    Zhou Yu et al, 2023, Biochemical Pharmacology CrossRef
  237. Mechanistic Study of Macranthoside B Effects on Apoptotic Cell Death in Human Cervical Adenocarcinoma Cells
    Y. Li et al, 2022, Fol. Biol. CrossRef
  238. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer
    Mateusz Wylaź et al, 2023, Biomedicine & Pharmacotherapy CrossRef
  239. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
    Karina A. Miller et al, 2023, Oncogene CrossRef
  240. Safety and Toxicology Study of Hu7691, a Novel AKT Inhibitor, following Oral Administration in Rats
    Renhua Gai et al, 2023, Toxics CrossRef
  241. Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity
    Sirui Zhang et al, 2023, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  242. Akt, IL-4, and STAT Proteins Play Distinct Roles in Prostaglandin Production in Human Follicular Dendritic Cell-like Cells
    Jihye Jeong et al, 2023, IJMS CrossRef
  243. Exploring the molecular interactions and binding affinity of resveratrol and calcitriol with RAGE and its intracellular proteins and kinases involved in colorectal cancer
    Yadav Sangeeta Muthyalaiah et al, 2023, Journal of Biomolecular Structure and Dynamics CrossRef
  244. Design, synthesis and bioevaluation of novel prenylated chalcones derivatives as potential antitumor agents
    Jia Yu et al, 2023, European Journal of Pharmaceutical Sciences CrossRef
  245. Tools for investigating O-GlcNAc in Signaling and other Fundamental Biological Pathways
    Zachary M. Nelson et al, 2023, Journal of Biological Chemistry CrossRef
  246. Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation
    Emily C. Erickson et al, 2024, Sci. Signal. CrossRef
  247. Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises
    Kosmas Alexandros Pervanidis et al, 2024, J. Med. Chem. CrossRef
  248. Anthriscus sylvestris—Noxious Weed or Sustainable Source of Bioactive Lignans?
    Sanja Berežni et al, 2024, Plants CrossRef
  249. Strategies and techniques for preclinical therapeutic targeting of PI3Kin oncology: where do we stand in 2024?
    Yanyan Liu et al, 2024, Expert Opinion on Therapeutic Targets CrossRef
  250. Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells
    Cong Si Tran et al, 2024, Gastroenterology CrossRef
  251. Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Ranran Su et al, 2024, Cell Death Discov. CrossRef
  252. Oncogenes and tumor suppressor genes: functions and roles in cancers
    Tikam Chand Dakal et al, 2024, MedComm CrossRef
  253. Chlorogenic Acid and Cinnamaldehyde in Combination Inhibit Metastatic Traits and Induce Apoptosis via Akt Downregulation in Breast Cancer Cells
    Yusuff Olayiwola et al, 2024, IJMS CrossRef
  254. Targeting the RAS upstream and downstream signaling pathway for Cancer treatment
    Md. Arafat Hossain, 2024, European Journal of Pharmacology CrossRef
  255. Search of Allosteric Inhibitors and Associated Proteins of an AKT-like Kinase from Trypanosoma cruzi.
    Rodrigo Ochoa et al, 2018, Int J Mol Sci CrossRef
  256. null
    Meshach Asare-Werehene et al, 2024 CrossRef
  257. One Hundred Faces of Geraniol
    Wanda Mączka et al, 2020, Molecules CrossRef
  258. Development of Novel Pyridine and Pyrimidine Clubbed Bisindoles as Inhibitors of AKT Pathway
    Lisha K. Poonacha et al, 2024, ChemistrySelect CrossRef
  259. Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy
    Mehlika Dilek Altıntop et al, 2024, European Journal of Medicinal Chemistry CrossRef
  260. A chalcone derivative SBD-2 exerts anticancer effects in human colorectal cancer cells
    Bowen Zheng et al, 2024, Futur J Pharm Sci CrossRef
  261. mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors
    Constance A. Sobsey et al, 2024 CrossRef
  262. Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC
    Junxia Ma et al, 2024, Front. Pharmacol. CrossRef
  263. Autoinhibited Protein Database: a curated database of autoinhibitory domains and their autoinhibition mechanisms
    Daeahn Cho et al, 2024 CrossRef
  264. Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications
    Mazen Abdulrahman Binmujlli, 2024, Molecules CrossRef
  265. The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer
    Federico Rebaudi et al, 2024, Cancer Treatment Reviews CrossRef
  266. The Evolution of Small-Molecule Akt Inhibitors from Hit to Clinical Candidate
    Gengren Tian et al, 2024, European Journal of Medicinal Chemistry CrossRef
  267. null
    , 2025 CrossRef
  268. Lessons learned from 20 years of preclinical testing in pediatric cancers
    Malcolm A. Smith et al, 2024, Pharmacology & Therapeutics CrossRef
  269. 2,2’- Bipyridine Derivatives Exert Anticancer Effects by Inducing Apoptosis in Hepatocellular Carcinoma (HepG2) Cells
    - Priyanka et al, 2024, JHC CrossRef
  270. AKT kinases as therapeutic targets
    Dalal Hassan et al, 2024, J Exp Clin Cancer Res CrossRef
  271. Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma
    Leanne Stevenson et al, 2024, Sci Rep CrossRef
  272. Identification of Natural Phytochemicals as AKT2 Inhibitors Using Molecular Docking and Dynamics Simulations as Potential Cancer Therapeutics
    Jibon Kumar Paul et al, 2025, Heliyon CrossRef
  273. In vivo antitumor activity of PHT-427 inhibitor-loaded polymeric nanoparticles in head and neck squamous cell carcinoma
    Joaquín Yanes-Díaz et al, 2025, Drug Delivery CrossRef
  274. The PI3K/Akt pathway: a target for curcumin’s therapeutic effects
    Mahdieh Aliyari et al, 2025, J Diabetes Metab Disord CrossRef